Navigation Links
CorMatrix Cardiovascular Announces First European Implants of CorMatrix(R) ECM Technology(TM)
Date:3/5/2009

ATLANTA, March 5 /PRNewswire/ -- CorMatrix Cardiovascular, Inc., an Atlanta-based company dedicated to developing and delivering unique extracellular matrix (ECM Technology) biomaterial devices that harness the body's innate ability to repair damaged cardiovascular tissue, announced today that it has begun its expansion in Europe following the first use of the CorMatrix(R) ECM Technology(TM) in a patient undergoing cardiac surgery.

The first device implanted in Europe was completed by Professor Stephan Jacobs, M.D., and Professor Volkmar Falk, M.D., both of University Hospital Zurich in Switzerland, who utilized the CorMatrix ECM Technology to close the pericardium of a 70-year-old patient following triple coronary artery bypass graft (CABG) surgery.

"We are pleased with the ease of use of the CorMatrix ECM(TM) and welcome this technology into our surgical protocol," commented Dr. Jacobs. "This is an advancement in cardiac surgery to restore the patient's normal anatomical structures, which we believe is in the patient's best interest."

"Closure of the pericardium is beneficial as it restores the natural barrier between the heart and the chest wall; it protects the heart, underlying grafts that were applied to the heart, and makes it easier and safer to re-access the heart if a subsequent procedure is required," said Robert G. Matheny, M.D., Chief Scientific Officer of CorMatrix Cardiovascular.

Following implantation by a surgeon, the CorMatrix ECM Technology acts as a scaffold into which the patient's own cells migrate and integrate, stimulating the body's innate wound-healing mechanisms to repair tissue at the site of implantation. As the patient's cells populate the matrix, they lay down their own collagen, which matures over time to form a functional tissue repair. The implanted ECM(TM) material is gradually replaced and reabsorbed by the body as the patient's tissue is remodeled.

"Our European launch further validates the increasing interest and acceptance that our ECM Technology continues to receive among the clinical community. Because our ECM Technology supports native tissue repair, it represents a significant advancement over currently available materials," said Beecher Lewis, President and Chief Operating Officer of CorMatrix Cardiovascular. "We are pleased to have achieved this important milestone and plan to continue to lead the way toward other significant advancements for cardiac surgeons and their patients."

The use of extracellular matrix technology in non-cardiovascular applications has established a significant foothold with over 500,000 procedures performed to date in soft tissue repair, wound management and orthopedic applications. Since the launch of the CorMatrix(R) ECM(TM) for Pericardial Closure, the technology has been used at more than 220 hospitals across the U.S. and has been implanted in more than 10,000 cardiac procedures.

About CorMatrix(R) ECM Technology(TM)

CorMatrix Cardiovascular holds an exclusive license from Purdue University to research, develop, manufacture and market naturally occurring ECM(TM) products for cardiovascular applications. The company currently has U.S. clearance and European approval with a CE Mark for its ECM Technology as an implant for pericardial closure, and clearance in the U.S. for use in cardiac tissue repair.

About CorMatrix Cardiovascular, Inc.

CorMatrix Cardiovascular, a privately held company based in Atlanta, Georgia, is dedicated to developing and delivering innovative cardiovascular devices that harness the body's own innate ability to remodel damaged tissue. For more information, visit www.cormatrix.com.


'/>"/>
SOURCE CorMatrix Cardiovascular, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Number of cardiovascular risk factors could determine safety of intravenous gammaglobulin treatment
2. Big-hearted fish reveals genetics of cardiovascular condition
3. ESC reaffirms advice on cardiovascular risks associated with long-haul flights
4. Systolic and diastolic blood pressures together more useful for predicting cardiovascular risk
5. Exploring Genetic Link Between Migraines, Cardiovascular Trouble
6. St. Mary Medical Center Opens New Cardiovascular Catheterization Labs Reaffirming Role as a Regional Leader in Cardiovascular Medicine
7. Cardiovascular Disease and Diabetes: New Blog and Slide Presentation on the Diabetes Best Practices Website Discuss the Most Recent Studies in this Field
8. Womens Heart Health a Critical Focus at Northwestern Memorials Bluhm Cardiovascular Institute
9. Omega-6 PUFAs and risk of cardiovascular disease
10. FluoroPharma Obtains US Patent for Imaging Cardiovascular Plaque using FDG
11. Diabetes and Cardiovascular Disease: Online Presentation Looks at the Complex Relationship of These Two Diseases in Light of Recent Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
(Date:10/12/2017)... ... 2017 , ... HMP , a leader in healthcare events and education, today ... Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & ... award competition recognizes editorial and design excellence across a range of sectors. This year’s ...
(Date:10/12/2017)... Mich. (PRWEB) , ... October 12, 2017 , ... ... has been named one of Michigan’s 2017 Best and Brightest in Wellness® by ... Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)...  BioPharmX Corporation (NYSE MKT: BPMX) researchers were part ... way to use nonlinear optical imaging to confirm the ... A presentation ... how researchers from BioPharmX and the Wellman Center for ... suite of imaging techniques in what is called "Pharmacokinetic ...
(Date:10/10/2017)... received FDA 510(k) clearance in May 2017 for its highly anticipated ... for endoscopy environments. An innovative secondary monitor solution, ZeroWire Mobile ... the improvement of patient outcomes, procedural efficiency, and the lowering of ... ... By ...
(Date:10/4/2017)... 2017  South Korean-based healthcare product Development Company I.M. ... on Kickstarter. The device will educate the user about ... better efficiency compared to the dated and pricey CPR ... efficacy of the compression for a more informed CPR ... to raise $5,000. ...
Breaking Medicine Technology: